1. Does PSA Testing Influence the Natural History of Prostate Cancer?
John Anderson 
European Urology Supplements 
Volume 1, Issue 5, Pages 3-10 (August 2002)
DOI: /S (02)

2. Fig. 1
Disease-specific mortality by tumour grade in a cohort of 451 men aged 65–75 years at diagnosis and managed conservatively [10] (reproduced with permission).
European Urology Supplements 2002 1, 3-10DOI: ( /S (02) )

3. Fig. 2
Trial profile of the Quebec Prostate Cancer Screening Program (man-years [m-y]) [21] (reproduced with permission).
European Urology Supplements 2002 1, 3-10DOI: ( /S (02) )

4. Fig. 3
Proportion of men in the ERSPC and PLCO studies with a screening indication for biopsy [23] (reproduced with permission).
European Urology Supplements 2002 1, 3-10DOI: ( /S (02) )

5. Fig. 4
Age-adjusted rates of prostate cancer: (a) incidence, and (b) mortality in the SEER Program, 1973–1996. The shaded areas on the figures represent the period following the introduction of PSA testing [24] (reproduced with permission).
European Urology Supplements 2002 1, 3-10DOI: ( /S (02) )